Recently Presented Scientific Abstracts

If you missed TMDs Symposium at ASCO 2008... "Mutations in Solid Tumor Malignancies" follow this link For The Presentations June 1st, 2008

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 February 1st, 2007

Regulation of Survivin by ErbB2 Signaling February 1st, 2006

Inhibition of ErbBII2 By Small Molecule Tyrosine Kinase Inhibitors, But Not Trastuzumab, Affects Metabolic Pathways: Implications To Cardiac Toxicity December 15th, 2006

Immunohistochemical (IHC) assessment of transforming growth factor alpha (TGF- ) in conjunction with epidermal growth factor receptor (EGFR) as potential determinants of response to EGFR-targeted therapy in patients with advanced colorectal cancer (CRC). 2006 AACR Molecular Diagnostics in Cancer Therapeutic Development

Heterogeneity of epidermal growth factor receptor (EGFR) expression and variation in immunohistochemistry IHC testing may affect access to EGFR-targeted therapy in patients with advanced colorectal cancer (CRC) Abstract #10104, 2006 ASCO Annual Meeting

Therapeutic implications for acquired resistance and heart toxicity using targeted therapy to erbB2 Abstract #3084, 2006 ASCO Annual Meeting

EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response Poster Presentation #502 2006 ASCO Annual Meeting – Biomarker work for this study was conducted by TMD. Please click here for link to presentation (ASCO membership required to view before September, 2006).

Abstracts

Comparison of EGFR Assay Results from the Community with a Central Laboratory, Poster presentation #301, 2006 ASCO GI Symposium

Evaluation of a Novel Diagnostic Algorithm for Determination of EGFR Expression, Poster presentation #302, 2006 ASCO GI Symposium

Comparison of “False Negative” EGFR Results Between Reference and Hospital Laboratories - Implications for Clinical Practice, Poster presentation #303, 2006 ASCO GI Symposium

Resistance to erbB targeted therapy in breast cancer, Poster presentation, 2005 San Antonio Breast Cancer Symposium / AACR–EORTC Molecular Targets and Cancer Therapeutics

A single arm, multicenter, open label, phase II study of lapatinib as 2nd line treatment of patients with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract, Abstract #4594, 2005 ASCO Annual Meeting

Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer, Abstract #3004, 2005 ASCO Annual Meeting